Press Releases

April 2, 2018 • 9:49 AM EDT

Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City

March 28, 2018 • 1:41 PM EDT

Amarantus Completes Tender Exchange of Convertible Securities; CEO attending CNBC's Healthy Returns conference in New York City

March 8, 2018 • 8:00 AM EST

Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia

March 5, 2018 • 8:00 AM EST

Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum

March 1, 2018 • 6:00 AM EST

MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231

February 26, 2018 • 5:56 PM EST

Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding

January 29, 2018 • 9:00 AM EST

Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease

January 23, 2018 • 9:59 AM EST

Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

January 9, 2018 • 10:59 AM EST

Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018

January 4, 2018 • 9:45 AM EST

Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS